전위의존성 칼륨 채널 서브패밀리 KQT 멤버 2 : 파이프라인 리뷰

전위의존성 칼륨 채널 서브패밀리 KQT 멤버 2(Potassium Voltage Gated Channel Subfamily KQT Member 2)를 표적으로 한 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업이나 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트, 최신 뉴스와 발표 등의 정보를 전해드립니다.

서론

• 조사 범위

전위의존성 칼륨 채널 서브패밀리 KQT 멤버 2 개요

치료제 개발

• 개발중인 제품 : 개발 단계별
• 개발중인 제품 : 치료 영역별
• 개발중인 제품 : 증상별

파이프라인 제품 상황 개요

• 후기 단계 제품
• 초기 단계 제품
• 개발 단계가 불명확한 제품

기업에서 개발중인 제품

대학/기관에서 개발중인 제품

치료제 평가

• 단독치료 제품(Monotherapy Products)/병용 제품(Combination Products)별
• 작용기전별
• 투여 경로별
• 분자 종류별

치료제 개발에 참여하고 있는 기업

• 1st Order Pharmaceuticals Inc
• Bristol-Myers Squibb Company
• Grunenthal GmbH
• Saniona AB
• SciFluor Life Sciences, LLC
• Valeant Pharmaceuticals International, Inc.

약제 개요

개발이 중지된 제품

주요 뉴스 및 프레스 릴리스

부록

도표

※ 이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Summary

Global Markets Direct's, 'Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016', provides in depth analysis on Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) targeted pipeline therapeutics.

The report provides comprehensive information on the Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

• The report provides a snapshot of the global therapeutic landscape for Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2)
• The report reviews Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) targeted therapeutics and enlists all their major and minor projects
• The report assesses Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) targeted therapeutics

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

• Table of Contents
  • List of Tables
  • List of Figures
• Introduction
  • Global Markets Direct Report Coverage
• Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) Overview
• Therapeutics Development
  • Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Products under Development by Stage of Development
  • Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Products under Development by Therapy Area
  • Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Products under Development by Indication
• Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Products Glance
  • Late Stage Products
  • Early Stage Products
  • Unknown Stage Products
• Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Products under Development by Companies
• Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Products under Development by Universities/Institutes
• Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Therapeutics Assessment
  • Assessment by Monotherapy/Combination Products
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
• Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Companies Involved in Therapeutics Development
  • 1st Order Pharmaceuticals Inc
  • Bristol-Myers Squibb Company
  • Grunenthal GmbH
  • Knopp Biosciences LLC
  • Saniona AB
  • SciFluor Life Sciences LLC
  • Valeant Pharmaceuticals International Inc
• Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Drug Profiles
  • 1OP-2198 - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • ezogabine - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • NH-34 - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • RL-81 - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • SF-0034 - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • Small Molecule to Activate Kv7.2 and Kv7.3 Channels for Epilepsy and Pain - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • Small Molecule to Activate Kv7.2 for Neuropathic Pain - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • Small Molecules to Activate KCNQ and TSPO for Pain - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • Small Molecules to Activate KCNQ2 and KCNQ3 Channels for Chronic Pain and CNS disorder - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • Small Molecules to Activate Kv7.2 for Neuropathic Pain, Epilepsy and Tinnitus - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
• Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Discontinued Products
• Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Featured News & Press Releases
  • Feb 22, 2016: Patheon Selected by Grunenthal to Develop Drugs Using INTAC Abuse Deterrent Formulations Technology
  • Jun 19, 2015: SciFluor Life Sciences Patented Compound SF0034 Highlighted in Research Published in The Journal of Neuroscience
  • Apr 16, 2015: The ALS Association, Harvard Stem Cell Institute, and Massachusetts General Hospital Neurological Clinical Research Institute Collaborate with GlaxoSmithKline on New ALS Clinical Trial
  • Feb 04, 2015: Anti-epilepsy drug preserves brain function after stroke
  • Jan 08, 2015: SciFluor Life Sciences Awarded U.S. Patent for KCNQ2/3 Activator Designed for Treatment of Epilepsy and Related Neurological Disorders
  • Jun 25, 2013: SciFluor Life Sciences Presents New Preclinical Data For SF0034 At 30th International Epilepsy Congress
  • May 31, 2013: EMA's CHMP Recommends Restricting Trobalt To Last-line Therapy In Partial Epilepsy
  • May 27, 2013: Valeant Pharma's Retigabine Shows Promise In Preventing Noise-induced Tinnitus In Animal Model, Pitt Researchers Report
  • Jul 27, 2011: Glaxosmithkline's Drug Retigabine Added To NHS Treatment Options
  • Jun 16, 2011: Retigabine May Further Help People With Epilepsy, NICE Says
  • Jun 13, 2011: Valeant And GlaxoSmithKline Announce FDA Approval For Potiga
  • Apr 18, 2011: GSK And Valeant Respond To FDA On Ezogabine
  • Mar 29, 2011: GSK And Valeant Receive European Authorization For Trobalt
  • Jan 21, 2011: GSK And Valeant Receive Positive Opinion In Europe From CHMP For Trobalt
  • Dec 01, 2010: GSK And Valeant Receive FDA Complete Response Letter For Ezogabine
• Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

• Number of Products under Development for, H2 2016
• Number of Products under Development by Therapy Area, H2 2016
• Number of Products under Development by Indication, H2 2016
• Comparative Analysis by Late Stage Development, H2 2016
• Comparative Analysis by Early Stage Products, H2 2016
• Comparative Analysis by Unknown Stage Development, H2 2016
• Number of Products under Development by Companies, H2 2016
• Products under Development by Companies, H2 2016
• Number of Products under Investigation by Universities/Institutes, H2 2016
• Products under Investigation by Universities/Institutes, H2 2016
• Assessment by Monotherapy/Combination Products, H2 2016
• Number of Products by Stage and Mechanism of Action, H2 2016
• Number of Products by Stage and Route of Administration, H2 2016
• Number of Products by Stage and Molecule Type, H2 2016
• Pipeline by 1st Order Pharmaceuticals Inc, H2 2016
• Pipeline by Bristol-Myers Squibb Company, H2 2016
• Pipeline by Grunenthal GmbH, H2 2016
• Pipeline by Knopp Biosciences LLC, H2 2016
• Pipeline by Saniona AB, H2 2016
• Pipeline by SciFluor Life Sciences LLC, H2 2016
• Pipeline by Valeant Pharmaceuticals International Inc, H2 2016
• Discontinued Products, H2 2016

List of Figures

• Number of Products under Development for, H2 2016
• Number of Products under Development by Therapy Area, H2 2016
• Number of Products under Development by Top 10 Indication, H2 2016
• Comparative Analysis by Early Stage Products, H2 2016
• Assessment by Monotherapy/Combination Products, H2 2016
• Number of Products by Stage and Mechanism of Actions, H2 2016
• Number of Products by Routes of Administration, H2 2016
• Number of Products by Stage and Routes of Administration, H2 2016
• Number of Products by Stage and Molecule Type, H2 2016